Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line
- 9 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 111 (6), 812-825
- https://doi.org/10.1007/s12185-020-02843-8
Abstract
We herein report the results of the New TARGET study 2nd-line, which collected data on patients with chronic-phase (CP) chronic myeloid leukemia (CML) who received a 2nd-line tyrosine kinase inhibitor (TKI) because of resistance and/or to a 1st-line TKI. A total of 98 patients were enrolled intolerance between April 2010 and March 2013, and 82 patients were analyzed. The median age was 54 years (range 22–88 years). Seventy-six patients (93%) received imatinib as the 1st-line TKI. Forty-five (55%) and 37 (45%) patients began nilotinib and dasatinib treatments at entry, respectively. First-line TKI treatment achieved complete hematological response in 79 patients (96%) and complete cytogenetic response (CCyR) in 49 patients (60%), respectively. Nine patients (11%) had BCR-ABL1 kinase domain point mutations at enrollment. The estimated 3-year progression-free-survival rate after enrollment was 98.7% (95% CI 91.1–99.8%). Overall, the probabilities of achieving CCyR and a major molecular response were 89.3% (95% CI 81.4–94.8%) and 87.2% (95% CI 78.1–93.8%), respectively. There were no new safety issues. This study demonstrated that CML-CP patients in Japan who are resistant and/or intolerant to a 1st-line TKI can achieve an extremely good outcome by 2nd-line TKI treatment.Keywords
Funding Information
- Novartis Pharmaceuticals
- Bristol-Myers Squibb
This publication has 30 references indexed in Scilit:
- Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET systemInternational Journal of Hematology, 2019
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Differences in incidence and trends of haematological malignancies in Japan and the United StatesBritish Journal of Haematology, 2013
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood, 2011
- Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET systemLeukemia Research, 2011
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood, 2011
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibHaematologica, 2010
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid LeukemiaClinical Cancer Research, 2009
- Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Cancer Control, 2009
- Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSHInternational Journal of Hematology, 2008